CRISPR-Based Point-of-Care Diagnostics for Antimicrobial Resistance: From Molecular Precision to Clinically Deployable Bioengineering Systems
Article Sidebar
Main Article Content
Abstract
The issue of antimicrobial resistance (AMR) has become a defining feature of global health, driven not only by microbial evolution but also by persistent delays in delivering actionable diagnostic information to clinicians. Although molecular technologies have significantly enhanced pathogen characterization, their clinical utility remains constrained by centralized infrastructure, lengthy turnaround times, and limited accessibility in resource-restricted settings. Based on programmable guide RNAs and the collateral cleavage activity of Cas enzymes, CRISPR-based nucleic-acid diagnostics have rapidly evolved into point-of-care (POC) testing applications. However, analytical sensitivity is no longer the primary barrier to clinical translation; instead, challenges related to engineering robustness in complex biological matrices, multiplex resistance detection, workflow automation, reagent stability, and clinical performance have become dominant. This Perspective re-evaluates CRISPR-based AMR testing as an integrated bioengineering system rather than a single molecular assay. We trace key translational bottlenecks and propose system-level benchmarks required to transition CRISPR diagnostics from experimental platforms into clinically deployable tools supporting antimicrobial stewardship and surveillance programs.
Downloads
Article Details
Copyright (c) 2026 Vijayasimha M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Huang Z, Lyon CJ, Wang J, Lu S, Hu TY. CRISPR-based diagnostics: from molecular mechanisms to clinical applications. Adv Sci. 2023;10:2301697. Available from: https://doi.org/10.1002/advs.202301697
Zhou J, Li Z, Olajide JS, Wang G. CRISPR/Cas nucleic acid detection systems: advances and challenges. Heliyon. 2024;10:e26179. Available from: https://doi.org/10.1016/j.heliyon.2024.e26179
Ortiz-Cartagena C, Torres-Viera C, Jenkins SG, Whittier S, Chen L. Rapid detection of OXA-48 and GES carbapenemases using CRISPR-Cas13a. Microbiol Spectr. 2023;11:e01329-23. Available from: https://doi.org/10.1128/spectrum.01329-23
Sohail S, Imran M, Qureshi A. Rapid visual detection of carbapenemase genes using RPA-CRISPR/Cas12a. Biosensors. 2024;14:536. Available from: https://doi.org/10.3390/bios14110536
Shin J, Kim SR, Xie Z, Jin YS, Wang YC. CRISPR/Cas12a detection of carbapenem-resistant Enterobacterales. Biosensors. 2024;14:194. Available from: https://doi.org/10.3390/bios14040194
Gong S, Liu Y, Zhang Y. Ultrasensitive RNA detection using CRISPR-Cas12a. Analyst. 2024;149:4418–4424. Available from: https://doi.org/10.1039/D4AN00479E
Wang L, Zhang X, Chen Y. Split-crRNA-enabled multiplex CRISPR-Cas12a logic circuits. Nat Commun. 2024;15:52691. Available from: https://doi.org/10.1038/s41467-024-52691-x
Zhang J, Liu H, Wang Y. Integrated CRISPR/Cas12a microarray diagnostics. ACS Nano. 2024;18:17345–17357. Available from: https://doi.org/10.1021/acsnano.4c05734
Zhou Z, Sun Y, Yang X. DSAC-Cas12a enables rapid amplification-free nucleic-acid detection. ACS Omega. 2024;9:31744–31752. Available from: https://doi.org/10.1021/acsomega.4c03413
Chen A, Li Y, Wang R. Amplification-free OR-gated CRISPR cascade detection. Proc Natl Acad Sci U S A. 2025;122:e2420166122. Available from: https://doi.org/10.1073/pnas.2420166122
Chen L, Hu M, Zhou X. Engineering one-pot CRISPR diagnostic strategies for point-of-care testing. Trends Biotechnol. 2025;43:98–110. Available from: https://doi.org/10.1016/j.tibtech.2024.07.007
Kongkaew R, Uttamapinant C, Patchsung M. Freeze-dried CRISPR diagnostics for point-of-care use. J Vis Exp. 2024;210:e66703. Available from: https://doi.org/10.3791/66703